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Lower hemoglobin is associated with cognitive impairment and Alzheimer's 
disease (AD). Since brain iron homeostasis is perturbed in AD, we investigated 
whether this is peripherally reflected in the hematological and related blood 
chemistry values from the Australian Imaging Biomarker and Lifestyle (AIBL) study (a 
community-based, cross-sectional cohort comprising 768 healthy controls (HC), 133 
participants with mild cognitive impairment (MCI) and 211 participants with AD). We 
found that individuals with AD had significantly lower hemoglobin, mean cell hemoglobin 
concentrations, packed cell volume and higher erythrocyte sedimentation 
rates (adjusted for age, gender, APOE-ε4 and site). In AD, plasma iron, transferrin, 
transferrin saturation, and red cell folate levels exhibited a significant distortion of their 
customary relationship to hemoglobin levels. There was a strong association 
between anemia and AD (adjusted OR=2.43 (CI[1.31, 4.54])). Moreover, AD emerged 
as a strong risk factor for anemia on step-down regression, even when controlling for all 
other available explanations for anemia (adjusted OR=3.41 95%CI[1.68, 6.92]). These 
data indicated that AD is complicated by anemia, which may itself contribute to cognitive 
decline. 
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 115.4 million cases of Alzheimer's disease (AD) world-wide are expected by 
2050,1 an impetus to understand this incurable dementia. AD and unexplained anemia 
are the most common diagnoses in nursing homes, both with a prevalence of ≈45% in 
this setting.2,3 Several reports have associated lower hemoglobin and anemia on a 
cross-sectional basis with poorer cognition,4-6 and recently low hemoglobin has featured 
on a biomarker panel with high diagnostic accuracy for AD.7 Two prospective studies of 
elderly populations have reported that anemia and lower levels of hemoglobin were 
associated with a ≈2-fold increased hazard for developing AD over ≈3 years.2,8 These 
studies speculated that low hemoglobin could be a systemic manifestation of AD. 
 Hemoglobin is the most abundant iron-protein in the body but is also synthesized 
in cortical neurons, where iron metabolism is severely perturbed in AD. Neocortical 
neurons in AD have decreased hemoglobin levels9, and elevated iron levels that 
promote oxidative damage.10,11 Genetic evidence supporting a role for abnormal iron-
associated metabolism in AD includes a risk polymorphism of hemoglobin12 and a 
synergistic risk effect for variants of iron-regulatory genes transferrin with HFE.13, 14 APP 
plays an important role in cellular iron export.11,15 An increase in IRP1 binding to the 
APP Iron Responsive Element in erythrocytes in AD compared to age-matched controls 
indicates that the central abnormality of hemoglobin and iron regulation in AD might be 
reflected in the blood.16. 
 In the present study, we investigated the association of AD with anemia and the 
causes of anemia in AD. We analyzed iron-related blood biochemistry, hemoglobin and 
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other blood chemistry values that may impact on anemia in the large Australian 
Imaging, Biomarker and Lifestyle (AIBL) cohort of healthy controls (HC), mild cognitive 






Material and Methods 
Study design and participants 
 Recruitment and characteristics of this cohort were previously described17. AIBL 
is a two-site (Melbourne, Perth), prospective study of aging, integrating data from 
neuroimaging, biomarkers, clinical and neuropsychological measurements and lifestyle 
information. Volunteers are in cohorts of: a.) AD by NINCDS-ADRDA criteria, b.) Mild 
Cognitive Impairment (MCI, associated with an increased risk for developing AD), and 
c.) cognitively healthy individuals (healthy controls, HC) (Supplementary Material, 
sections Participant Recruitment and Cohort Size for details). 
 AIBL was approved by the institutional ethics committees of Austin Health, St. 
Vincent’s Health, Hollywood Private Hospital, and Edith Cowan University. Written 
informed consent was obtained from all study participants. 
 
Procedures 
 Baseline blood samples were taken from overnight fasting participants, and 
fractionated or forwarded to clinical pathology laboratories for analysis as described1 
(Supplementary Material, section Biochemistry for details). Anemia diagnosis is detailed 
in Supplementary Material, section Anemia Diagnosis. All participants were given the 
Food Frequency Questionnaire developed by the Cancer Council of Victoria 







 Analysis was performed with R version 2.15.2 (packages, Supplementary 
Material, sections Statistical Analysis). Pearson’s χ2 assessed differences in the 
distributions of the missing data, genders and APOE ε4 incidence. Analysis of variance 
(ANOVA) assessed difference in age across the clinical classifications, followed by 
Tukey honest significant differences to test the pairwise comparisons. 
 Clinical pathology data were checked for normality by inspection of histograms 
and quartile-quartile plots. For those that deviated from normality, Box-Cox18 analysis 
was performed. The transformed data were then checked for normality. 
 Analysis of covariance (ANCOVA) was used with age, gender and site as 
confounding variables (ApoE-ε4 genotype was initially included, but was identified as a 
non-significant main effect and was not included in the final models.) to test the 
difference between the clinical classifications and continuous data. False discovery 
rate19 (FDR) was used to correct for multiple testing. For the analysis of iron, dietary iron 
was also included as a confounding variable. The analysis of both serum and red cell 
folate were also adjusted for dietary folate. The results presented are the adjusted 
means and standard errors (SE). The pairwise analysis was corrected for multiple 
testing by controlling for FDR. Adjusted p-values are presented (Supplementary 
Material, sections Statistical Analysis for details). 
 Fisher Exact tests were used to analyze the number of subjects above or below a 






 Logistic regression was used to assess the odds ratio (OR) of having AD given 
the anemia state (true/false), and vice versa, i.e. OR of being anemic based on the 
cognitive classification (HC/AD) (Supplementary Material, sections Statistical Analysis 
for details). To compare the log odds estimates between two logistic regression models, 
model with all subjects included and one with the subject with anemia of inflammation 






 Data from the initial baseline cohort17 were analyzed. The HC group was 
significantly younger than the MCI and AD groups (p<0.001), and the MCI group was 
significantly younger than the AD group (p<0.01). There were significantly more females 
in the combined cohort, particularly in the HC and AD groups. The AD group had 
significantly more APOEε4 allele carriers compared to the HC (p<0.001) and the MCI 
(p=0.033) groups, and the MCI group had significantly more ε4 carriers than the HC 
group (p<0.001) (Supplementary Table 1). There were small numbers of missing 
biochemical data, but not biased to any clinical group (Supplementary Figure 1). 
 We initially examined 23 clinicopathology test results deemed relevant to red cell 
synthesis and iron metabolism. None of the adjusted (gender, site, age) mean values 
lay outside of the clinical reference ranges, but ANCOVA revealed significant 
differences across the three clinical groups for hemoglobin, MCH, MCHC, PCV, red cell 
folate (decreased in AD), ESR and haptoglobin (increased in AD), with a trend to 
decreased plasma iron in AD (Table 1). While transferrin was not significantly different 
across the clinical groups (p=0.905), transferrin levels declined more steeply with age in 
AD (p=0.045) (Supplementary Figure 2). 
 Pair-wise comparison of these eight values of interest across the clinical groups 
(figure 1A-H) revealed that iron, hemoglobin, MCH, MCHC, and PCV were significantly 
decreased in AD compared to HC, and ESR was significantly elevated in AD compared 
to HC. MCI values lay between the HC and AD values for iron, hemoglobin, MCH, and 





AD and MCI (HC>MCI>AD). ESR and PCV were significantly different only between 
MCI and AD (MCI≈HC). In the ANCOVA for plasma iron, dietary iron intake was not a 
significant confounder and was removed from the final model. While haptoglobin 
showed a significant difference across the clinical groups, the individual pairwise 
comparisons showed only a trend towards increase in AD (figure 1H). 
 Since there was a significant decrease in hemoglobin levels and red cell 
hemoglobin content in the AD cohort, we analyzed the association between anemia 
(WHO criteria20: males hemoglobin<130 g/L, females hemoglobin<120 g/L) and AD by 
logistic regression, finding a strong unadjusted association (OR=5.94 95%CI[3.13, 
9.94], p<0.001). Adjusted for known major AD risk factors, age, gender and APOE-ε4 
status, the OR for being diagnosed as AD if anemic in this cohort was 2.43 
(95%CI[1.30, 4.54], p=0.005) (table 2A), consistent with previous reports.4,8,21. 
Conversely, higher MCHC was protective for AD (OR= 0.62, 95%CI[0.48-0.80], 
p<0.001, adjusted for age, gender and APOE-ε4 status). 
 We then interrogated the reciprocal OR, for being anemic if diagnosed as AD, 
and controlled for confounders for the risk of anemia. As expected, increasing RDW, 
urea, ESR and erythropoietin, decreasing WCC, iron and ceruloplasmin all showed an 
association with anemia within the combined HC/AD cohort (table 2B). Surprisingly, 
increasing ferritin was associated with anemia, as was increasing red cell folate (but 
only in AD cases). AD emerged as a strong risk factor for anemia, even when controlling 
for all other available explanations for anemia (adjusted OR=3.41, 95%CI[1.68, 6.92], 





while zinc and copper deficiency are uncommon causes of anemia, plasma zinc and 
copper were not significant terms in the OR model (not shown). Non-steroidal anti-
inflammatory drugs (NSAIDs) may contribute to anemia by promoting GI bleeding, 
although we found no evidence of blood loss to account for the increased risk of anemia 
in the AD cohort. Nevertheless, χ2 tests indicated no bias in the number of subjects on 
NSAIDs compared to those not on NSAIDs between the anemic and non-anemic groups 
within in AD and HC cohorts (p = 0.552, p = 0.200, respectively, Supplementary Table 
S2). Acetylcholinesterase inhibitors can also potentially cause GI bleeding (by Mallory-
Weiss syndrome). χ2 testing showed no bias in the usage of acetylcholinesterase 
inhibitors between anemic AD and non-anemic AD subjects (p = 0.204, Supplementary 
Table S3).  
 Taken together, these data indicate that AD is associated with a proclivity to 
anemia that could not be explained by known risk factors. To explore possible 
explanations for the proclivity towards anemia identified in the AD cohort, we analyzed 
the proportional prevalence of abnormal clinical pathology results (outside the reference 
range). These were indeed more prevalent in the AD group compared to the HC and 
MCI groups (13 out of 29 tests, expanded to include white cell sub-population counts, 
Supplementary Table 4), with no abnormality being more prevalent in the HC cohort. 
Abnormal results in MCI patients lay in prevalence between HC and AD abnormalities. 
 The older age of the AD cohort could account for the increased prevalence of 
abnormal tests, so we created age-matched MCI and HC groups (Supplementary Table 





remained significantly greater than HC for low levels of hemoglobin (18.54 vs 7.47%, 
AD:HC), PCV (20.49% vs 12.03%), transferrin saturation (9.27% vs 3.78%), serum iron 
(5.85% vs 1.26%), and serum folate (8.33 vs 1.67%), with elevations of ESR (46.70% vs 
33.33%), haptoglobin (42.51% vs 30.25%), ferritin (17.56% vs 7.98%) and TSH (9.80% 
vs 3.77%) (table 3). Differences in dietary intake could not account for the increased 
prevalence of serum folate and iron abnormalities observed. 
 Confining this analysis to age-matched anemia cases only, no clinical pathology 
abnormality was significantly more prevalent between HC and AD cohorts 
(Supplementary Table 5). ANCOVA of the hematology and biochemical data, controlling 
for age and gender, revealed small differences between anemic AD and HC subjects 
(Supplementary Table 6) for MCHC, lymphocyte count, bilirubin, and transferrin 
saturation (males only), but did not reveal a clearly different signature between the AD 
and HC anemic subjects. 
 As reticulocyte counts were not available, we used plasma erythropoietin levels 
as an indication of drive for red cell production. As expected, elevated erythropoietin 
levels were observed in the anemic cohort (p=0.003, Supplementary Figure 3), and 
associated with anemia risk (OR 1.45 CI[1.10, 1.92], table 2B). ANCOVA, controlling for 
age, gender, site and clinical classification, revealed no significant difference in 
erythropoietin across the neurological categories (p=0.103, table 1).  
 When anemia cases were categorized on the basis of clinical pathology 
abnormalities, anemia of chronic inflammation (AI) was the only anemia category 





the age-matched HC group (16.7%, p<0.001; Supplementary Figure 4 and 
Supplementary Table 7).  
 AI is characterized by an elevation of interleukin-6 (IL-6).22 However, IL-6 was not 
elevated in the AD cohort (Table 1). ANCOVA (adjusted for age, gender and site) 
revealed an elevation of IL-6 in subjects with anemia (p = 0.005), but no interaction 
between IL-6, anemia and neurological category (p = 0.826). To determine the extent 
that the increased risk for anemia in the AD group is accounted for by AI, we compared 
two logistic models, model 1 (m1) using all subjects and model 2 (m2) where the AI 
subjects were removed. There was no change in the AD OR for anemia (OR difference 
[m1 – m2] -0.181 (95%CI[-1.79, 1.67], p = 0.807) when the AI subjects were removed. 
The risk for anemia in the AD cohort using m2 was still strong (adjusted OR=3.59, 
95%CI[1.68, 6.95], p = 0.002). Therefore, AI does not explain the increased prevalence 
of anemia in AD. 
 These findings suggest that AD patients may have a defect in hemoglobin 
synthesis of unknown etiology. To characterize this we examined the relationships 
between levels of hemoglobin and its substrates: plasma iron, transferrin, transferrin 
saturation, haptoglobin and red cell folate. Using multiple regression analysis 
(controlling for age, gender and clinical classification), the relationship between 
hemoglobin (as a product) and each factor (as a precursor) showed an inverted-U 
shaped quadratic association (p<0.001) for each clinical cohort. The associations of 
hemoglobin as a product of either plasma iron, transferrin level, transferrin saturation or 





hemoglobin levels dropped precipitously as the substrate levels approached the 
margins of the normal range. The haptoglobin-hemoglobin relationship was not affected 
by clinical classification (p=0.5472). For the relationship between hemoglobin and red 
cell folate there was a steeper decline in hemoglobin levels in AD patients who had red 
cell folate levels above 1000 nmol/L (figure 2D), recapitulating the surprising 
observation that elevated red cell folate increased the risk for anemia in AD patients 
only (table 2B). These relationships were not significantly perturbed in the MCI cohort. 
 The puzzling association of higher levels of red cell folate with anemia (table 2B, 
figure 2D), together with significantly lower red cell folate levels (-13%, table 1, figure 
1G) in the AD cohort, could reflect anomalous folate metabolism in AD. Serum folate 
levels were not significantly changed in AD (table 1). So we analyzed the age-matched 
cohort for participants who had the mismatched combination of abnormally low serum 
folate with normal (or elevated) red cell folate. This combination of results was indeed 
uncommon in the HC group (0.5%) but was significantly more frequent in the MCI 
(3.8%, p=0.005) and AD (6.6%, p<0.001) groups (Supplementary Table 8). Indeed, in 
AD it was more common than abnormally low red cell folate (Supplementary Table 8). In 
addition, the mean ratio of red cell to serum folate, reflecting the exchange of folate 
between intracellular and extracellular blood compartments, was significantly elevated in 
anemic AD subjects (figure 1I), with no change in anemic HC and MCI subjects, Since 
nutritional intake of folate did not explain the increased prevalence of anemia in AD, 
these data implicate altered exchange of folate between serum and red cells as 






Anemia is an established risk factor for cognitive loss, causally attributed to low 
oxygenation of obligatorily aerobic cortical tissue.2,4,5,21. In the AIBL cohort, people with 
anemia were 2.40-fold more likely to have AD (adjusting for age and APOE-ε4), and 
anemia emerged as a stronger potential risk factor for AD than aging 5 years (table 2A). 
These findings are consistent with a prospective study that reported anemia as a risk 
factor for AD, accelerating cognitive decline to a degree similar to aging 12 years.8 
Therefore, identifying and treating anemia in older age could be imperative. However, 
our findings indicate that management of anemia in AD may not be straightforward. AI 
was more common in the AD cohort, but neither AI nor other known causes could 
explain the increased risk for anemia or lower hemoglobin levels in AD. 
 Idiopathic anemia becomes prevalent in advanced age, and indeed, in the AIBL 
cohort reversible causes of anemia were rare and idiopathic anemia was the most 
common cause (Supplementary Figure 4 and Supplementary Table 7). Is it possible that 
an impairment of hemoglobin production is a systemic manifestation of AD, and that 
since sub-clinical AD pathology also becomes prevalent above the age of 60, could 
idiopathic anemia itself be etiologically related to AD? Abnormalities of red cells have 
been reported in studies of smaller AD cohorts.23-26 We found that on average, AD red 
cells are smaller, have less concentrated hemoglobin, sediment faster and have lower 
folate levels than HC red cells (figure 1). For these results, MCI red cells have values 





 As with idiopathic anemia, we could not ascertain a clear etiological explanation 
for the lowering of hemoglobin in AD, but we detected changes in systemic iron, folate 
metabolism, thyroid, and inflammation that could adversely impact hemoglobin 
production. Importantly, the relationships between hemoglobin and its iron-related 
precursors (serum iron, transferrin and transferrin saturation) were perturbed in AD 
(figure 2A-C). Unlike HC and MCI, hemoglobin levels in AD declined significantly unless 
serum iron, transferrin and transferrin saturation were in the middle of the normal range. 
Therefore, iron-related hemoglobin production may be brittle in AD. The significantly 
greater prevalence of abnormally high serum ferritin in AD (17.65%) compared to age-
matched HC subjects (7.98%, table 3) together with significantly lower plasma iron 
levels (figure 1A) and increased prevalences of abnormally low serum iron and 
transferrin saturation (table 3) in AD, argue that iron accumulates in tissue stores and is 
not adequately mobilized in AD. This is consistent with iron accumulation in the 
neocortex in AD.11  
 Folate deficiency is a risk factor for both dementia and anemia, and while we 
observed folate changes in AD, they could not be accounted for by nutritional deficiency 
or medication. Serum folate levels were not significantly changed In the AD group 
compared to the age-matched HC group, but subnormal levels were significantly more 
prevalent (8.33% vs 1.67%, table 3). This might be consistent with a nutritional problem, 
but red cell folate is a better reflection of long-term deficiency27 and while red cell folate 
levels were decreased in the AD group (figure 1G),28 subnormal levels were uncommon 





folate metabolism that could contribute to the increased prevalence of anemia in AD 
was evidenced by the brittle relationship between hemoglobin levels and red cell folate 
in AD (figure 2D), as well as the puzzling observation that increasing red cell folate 
strongly increases the risk for anemia in AD but not HC subjects (table 2B). Abnormal 
folate metabolism has been implicated in AD pathogenesis. A genome wide association 
study identified a significant association between polymorphisms of 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like protein and the 
risk for late-onset AD.29 A proteomic study found that methylenetetrahydrofolate 
dehydrogenase 1 levels are 32-fold elevated in erythrocytes in AD compared to 
controls.26 Folate is susceptible to oxidation, notably by elevated cytosolic iron.30 
 Hypothyroidism might also contribute to the increased incidence of anemia in AD 
since abnormally elevated TSH was more common (9.80%) than age-matched HC 
(3.77%, table 3). However, adjusted mean TSH levels were not lower in the AD cohort, 
indicating that the contribution of hypothyroidism to anemia in AD is limited. 
 Inflammation may play a role in lowering hemoglobin in AD, since we observed 
elevated ESR, suppressed serum iron, elevated ferritin, and suppressed transferrin in 
the AD cohort (tables 1 and 3), and AI was the only diagnostic category for anemia that 
was significantly more prevalent (+12.2%) in the AD cohort compared to HC 
(Supplementary Figure 4 and Supplementary Table 7). However, logistic regression 
analysis excluding AI cases still determined that AD was a risk factor for anemia, and 
inflammation does not explain the differential tendency to lower hemoglobin levels in AD 





appraising the tendency to anemia. 
 Therefore, the etiology of the 3.41-fold increase in anemia in AD involves 
perturbances of multiple systems for hemoglobin synthesis. Hemolysis could be 
excluded since haptoglobin was elevated in AD (table 1), as others have also 
reported31. While the mechanism of this idiopathic hemoglobin defect in AD remains to 
be determined, we note that Aβ binds hemoglobin,32 and hemoglobin accumulates in 
the hallmark cortical amyloid plaque and congophilic angiopathy of AD.33 Aβ is enriched 
in red cell membranes in AD compared to healthy controls,34,35 and oxidizes red cell 
hemoglobin,36 potentially contributing to anemia in AD. 
 With the caveat that this is a cross-sectional study and the subjects were 
recruited via advertising, so not a true random sample of the Australian population, our 
findings identify AD as a novel risk factor for anemia. Since low hemoglobin itself 
impairs cognition, and is a risk factor for AD, the hemoglobin lesion of AD may not be an 
epiphenomenon. The interrelationship between AD and hemoglobin warrants closer 
investigation as a potential target for intervention. 
 
Supplementary information is available at Molecular Psychiatry's website 
(http://www.nature.com/mp) 
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[reference range] HC MCI AD p-value 
Iron (µmol/L) 
[M:7-35, F:7-30] 21.93 (0.22) 21.28 (0.52) 20.76 (0.43) 0.079 
Transferrin (µmol/L) 
[M:23-43, F:23-46] 32.96 (0.18) 33.09 (0.45) 33.16 (0.4) 0.890
a 
Transferrin Saturation (%) 
[M:14 - 53, F:14-48] 27.02 (0.35) 26.37 (0.83) 25.66 (0.69) 0.289 
Ceruloplasmin (g/L) 
[0.17-0.55] 0.312 (0.002) 0.316 (0.005) 0.305 (0.004) 0.122 
Ferritin (µg/L) 
[M:15-200, F:30-370b] 120.25 (3.46) 115.08 (8.01) 114.40 (6.75) 0.828 
Hemoglobin (g/L) 
[M:130-180, F:120-160] 140.96 (0.4) 139.93 (0.95) 137.62 (0.82) 0.012 
RCC (x1012/L) 
[M:4.5-5.7, F:3.8-5.1] 4.51 (0.02) 4.51 (0.04) 4.44 (0.03) 0.117 
MCV (fL) 
[80-96] 91.35 (0.15) 91.09 (0.36) 90.99 (0.31) 0.642 
MCH (pg) 
[27-33] 31.20 (0.06) 31.00 (0.14) 30.85 (0.12) 0.044 
MCHC (g/L) [320-360] 341.54 (0.21) 340.21 (0.51) 338.78 (0.43) < 0.001 
RDW (%) [11-15] 13.36 (0.03) 13.29 (0.07) 13.37 (0.06) 0.650 
PCV (L/L) 
[M:0.4-0.5, F:0.35-0.45] 0.412 (0.001) 0.411 (0.003) 0.402 (0.002) 0.014 
ESR (mm/hr) 
[1-35] 11.07 (0.29) 10.88 (0.7) 13.12 (0.7) 0.029 
Serum folate (nmol/L)c 
[7-40] 946.39 (29.03) 847.46 (74.89) 887.74 (65.47) 0.468 
Red cell folate (nmol/L) c 
[230-1600] 970.56 (14.67) 901.38 (38.37) 862.96 (31.89) 0.014 
B12 (pmol/L) 
[120-680] 293.78 (4.77) 284.91 (10.96) 291.10 (9.62) 0.817 
Bilirubin (µmol/L) 
[<19] 11.85 (0.15) 11.98 (0.37) 11.37 (0.28) 0.324 
TSH (mU/L) 
[0.1-4.0] 1.60 (0.04) 1.67 (0.1) 1.67 (0.08) 0.817 
Haptoglobin (g/L) 
[0.3 – 2.0] 1.48 (0.03) 1.57 (0.09) 1.63 (0.08) 0.031 
Erythropoietin (pg/mL) d 




[4-11] 1.73 (0.01) 1.75 (0.02) 1.78 (0.02) 0.122 
Urea (mmol/L) 
[2.5 – 8.3] 1.78 (0.01) 1.77 (0.02) 1.79 (0.02) 0.122
e 
IL 6 (pg/mL) 
[<5] 1.68 (0.04) 1.85 (0.11) 1.74 (0.08) 0.367 
Table 1: Hematological and associated clinical chemistry mean values in the 
clinical categories. Age, gender and site-adjusted means (standard error) and 
adjusted p-values (ANCOVA, controlling for false discovery rate [FDR]) are shown for 
the three clinical classifications. 
a Interaction between clinical classification and age (p=0.046). 
b Female ferritin reference range: pre-menopause: 20-220µg/L, post-menopause: 30-
370 µg/L. 
c Adjusted for dietary folate intake. 
d Erythropoietin analysis performed on the non-imputed data. Reference range as 
defined by ARUP Laboratories. 




Factor Odds ratio (95% CI) P value 
A for Alzheimer's disease 
Non–anemic, APOE-ε4 non-carrier, 
healthy control Reference  
Age (per 5 yrs) 1.95 (1.71—2.21) <0.001 
APOE-ε4 carrier 5.52 (3.71—8.22) < 0.001 
Female 0.94 (0.63–1.39) 0.741 
Anemia 2.43 (1.31—4.54) 0.005 
MCHC (per 8 g/L) 0.62 (0.48-0.80) <0.001 
B for anemia 
Non-anemic, healthy control Reference  
WCC (per 1.8 x109/L) 0.47 (0.30-0.74) 0.001 
RDW (per 1%) 1.75 (1.37-2.24) < 0.001 
Ceruloplasmin (per 0.08 g/L) 0.53 (0.32-0.87) 0.012 
Ferritin (per 124 µg/L) 1.48 (1.19-1.84) 0.001 
Iron (per 7.29 µmol/L) 0.17 (0.09-0.32) < 0.001 
Urea (per 2 mmol/L) 1.75 (1.32-2.32) < 0.001 
ESR (per 12 mm/hr) 1.77 (1.37-2.29) < 0.001 
Erythropoietin (per 74 ng/L) 1.44 (1.10-1.89) 0.008 
Red cell folate [HC] (per 518 nmol/L 
increase) 0.97 (0.60-1.57) 0.914 
Red cell folate [AD] (per 518 nmol/L 
increase) 2.39 (1.36-4.22) 0.002 
Alzheimer's disease 3.41 (1.68-6.92) <0.001 
Table 2. Logistic regression analysis of risk factors. The odds ratios for the 
continuous variables were calculated for the interquartile ranges (except for age) of the 
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whole cohort. A. The odds ratios of having an AD diagnosis in the cohort, with reference 
to non–anemic, APOE-ε4 non-carrier, cognitively healthy controls. Anemia and MCHC 
emerged as significant adjusted risks for AD from the backwards step analysis, together 
with known risks, age and APOE-ε4 carrier status. Model fit statistics: Nagelkerke 
R2=0.391, c-statistic=84.4%, Somers' Dxy=0.688 and Brier score=0.111. B. The odds 
ratios of being anemic, with reference to non–anemic, cognitively healthy controls. 
Alzheimer’s disease emerged as a risk factor, even when adjusted for all known risk 
factors for anemia from the backwards step analysis. There was a significant interaction 
between clinical classification and red cell folate (p=0.002), so odd ratios are presented 
for both healthy controls and Alzheimer's disease. Model fit statistics: Nagelkerke 






 Below Reference Range Above Reference Range 





HC v AD 
p-value 





HC v AD 
p-value 
Fe 
[238, 108, 205] 3.09% 1.26% 1.85% 5.85% 0.016 0.093 0.009 2.00% 2.10% 0.93% 2.44% 0.735 0.948  
Transferrin 
[238, 108, 205] 2.36% 1.26% 3.70% 2.93% 0.299 0.630  1.27% 1.68% 1.85% 0.49% 0.425 0.750  
Transf’n Sat’n 
[238, 108, 205] 5.26% 3.78% 0.93% 9.27% 0.003 0.029 0.020 7.80% 5.88% 11.11% 8.29% 0.225 0.607  
Ceruloplasmin 
[238, 108, 205] 0.91% 1.67% 0.00% 0.49% 0.284 0.630  0.73% 1.26% 0.93% 0.00% 0.257 0.623  
Ferritin 
[238, 108, 205] 2.72% 2.94% 1.85% 2.93% 0.888 1.000  11.98% 7.98% 10.19% 17.56% 0.008 0.058 0.004 
Hemoglobin 
[241, 109, 205] 11.35% 7.47% 6.42% 18.54% 0.000 0.012 0.001 3.42% 2.07% 9.17% 1.95% 0.004 0.029 1.000 
RCC 
[241, 109, 205] 21.80% 21.16% 16.51% 25.37% 0.193 0.589  4.50% 3.32% 5.50% 5.37% 0.460 0.750  
MCV 
[241, 109, 205] 0.90% 0.41% 0.00% 1.95% 0.220 0.607  7.21% 6.64% 5.50% 8.78% 0.563 0.821  
MCH 
[241, 109, 205] 1.26% 0.41% 0.00% 2.93% 0.036 0.187 0.052 18.20% 21.16% 15.60% 16.10% 0.304 0.630  
MCHC 
[241, 109, 205] 0.36% 0.00% 0.00% 0.98% 0.174 0.562  0.00% 0.00% 0.00% 0.00% 1.000 1.000  
RDW 
[241, 109, 205] 0.00% 0.00% 0.00% 0.00% 1.000 1.000  6.85% 5.81% 5.50% 8.78% 0.414 0.750  
PCV 
[241, 109, 205] 14.23% 12.03% 7.34% 20.49% 0.003 0.029 0.019 2.70% 2.49% 5.50% 1.46% 0.130 0.503  
ESR 
[240, 107, 197] 1.10% 1.67% 0.00% 1.02% 0.503 0.774  33.82% 33.33% 11.21% 46.70% 0.000 0.000 0.006 
WCC 
[241, 109, 205] 5.59% 5.39% 9.17% 3.90% 0.158 0.539  1.44% 1.66% 1.83% 0.98% 0.725 0.948  
Neutrophils 
[241, 109, 205] 3.60% 4.15% 4.59% 2.44% 0.507 0.774  1.44% 1.66% 2.75% 0.49% 0.230 0.607  
Lymphocytes 
[241, 109, 205] 25.41% 23.24% 29.36% 25.85% 0.466 0.750  0.54% 0.00% 1.83% 0.49% 0.050 0.242 0.460 
Monocytes 
[241, 109, 205] 0.18% 0.41% 0.00% 0.00% 1.000 1.000  2.16% 2.90% 1.83% 1.46% 0.601 0.832  
Eosinophils 
[241, 109, 205] 0.00% 0.00% 0.00% 0.00% 1.000 1.000  2.70% 1.24% 5.50% 2.93% 0.075 0.335  
Basophils 






[240, 108, 205] 0.18% 0.00% 0.00% 0.49% 0.566 0.821  16.46% 14.58% 12.04% 20.98% 0.082 0.341  
Creatinine 
[240, 108, 205] 0.00% 0.00% 0.00% 0.00% 1.000 1.000  15.01% 15.00% 13.89% 15.61% 0.927 1.000  
Serum folate 
[240, 108, 204] 4.89% 1.67% 5.56% 8.33% 0.003 0.029 0.001 2.54% 2.50% 3.70% 1.96% 0.603 0.832  
Red cell folate 
[241, 109, 205] 3.42% 2.90% 3.67% 3.90% 0.826 1.000  5.77% 6.22% 5.50% 5.37% 0.971 1.000  
Vitamin B12 
[240, 108, 205] 3.44% 2.08% 3.70% 4.88% 0.258 0.623  6.51% 5.00% 7.41% 7.80% 0.432 0.750  
Bilirubin 
[239, 108, 205] 0.00% 0.00% 0.00% 0.00% 1.000 1.000  11.41% 10.88% 16.67% 9.27% 0.147 0.534  
TSH 
[239, 108, 204] 2.36% 2.09% 1.85% 2.94% 0.817 1.000  5.81% 3.77% 2.78% 9.80% 0.011 0.072 0.012 
Haptoglobin 
[238, 106, 207] 2.36% 2.52% 3.77% 1.45% 0.346 0.683  33.39% 30.25% 22.64% 42.51% 0.001 0.017 0.008 
IL-6 
[170, 82, 144] 0.00% 0.00% 0.00% 0.00% 1.000 1.000  10.35% 7.65% 12.20% 12.50% 0.280 0.630  
Erythropoietin 
[110, 48, 101] 11.20% 10.91% 6.25% 13.86% 0.139 0.750  10.42% 7.27% 12.50% 12.87% 0.353 0.683  
Table 3: Frequency of abnormal clinicopathology results in age-matched clinical cohorts. Frequency of results 
above or below the normal reference ranges, within each clinical diagnosis (healthy control, HC, mild cognitive 
impairment, MCI, age-matched to Alzheimer's disease, AD). P-values are from Fisher’s exact test for independence, 
testing across HC vs AD, and after FDR (Adj p-value). The pairwise comparison was only performed for where there was 
a significant difference across all three diagnoses. Bold reflects values that were significantly different on pairwise 






Figure 1. Changes in hematological and associated clinicopathology adjusted-
values in Alzheimer’s disease. Shown are pair-wise comparisons of clinicopathology 
values that are significantly different (on ANCOVA, Table 1) or showing a trend (iron) 
across the cohorts. A: iron, B: hemoglobin, C: mean cell hematocrit, D: mean cell 
hemoglobin concentration, E: erythrocyte sediment rate, F: packed cell volume, G: red 
cell folate, previously reported28, H: haptoglobin, I: the ratio of red cell to serum folate 
(rfol/sfol). Shown are the adjusted means (±SE) and p-values from ANCOVA adjusted 
for site, age and gender. HC, healthy controls; MCI, mild cognitive impairment, AD, 
Alzheimer's disease. 
 
Figure 2. The relationship of blood hemoglobin to precursor levels is perturbed 
in AD. Lines of best fit from linear regression models for hemoglobin as a product of A: 
plasma iron, B: plasma transferrin (quadratic relationship), C: transferrin saturation, D: 
red cell folate. Each shows a quadratic relationship. For all plots, age is fixed at the 
population mean (72.2 years). The grey shaded regions are the 95% confidence 
intervals. Solid lines- healthy controls, dotted lines- mild cognitive impairment, dashed 
lines- Alzheimer's disease. The red vertical lines indicate the min and max of the 
reference ranges. 
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